The global pharmacovigilance market, which covers medicine-safety monitoring, was valued at USD 9.35 billion in 2025 and is projected to rise from USD 10.45 billion in 2026 to USD 18.26 billion by 2031, representing an 11.78% compound annual growth rate. ResearchAndMarkets.com identifies expanding drug pipelines, advanced therapies, adverse drug reaction reporting, artificial intelligence and outsourcing to contract research organizations as major drivers. Contract outsourcing represented 54.88% of 2025 revenue, while Phase IV studies accounted for 32.05%. North America held 43.62% of the market in 2025, and Asia-Pacific is forecast to grow fastest at a 13.12% CAGR through 2031. Cybersecurity, data-privacy requirements and shortages of specialized personnel remain key constraints.